Vaxil Bio Ltd (VXL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vaxil Bio Ltd (VXL) has a cash flow conversion efficiency ratio of -0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-28.00K) by net assets (CA$667.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vaxil Bio Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Vaxil Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vaxil Bio Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaxil Bio Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sejahtera Bintang Abadi Textile Tbk
JK:SBAT
|
-0.023x |
|
Auston Capital Corp
V:ASTN-P
|
30.731x |
|
TOOSLA SA EO-08125
F:W6Q
|
N/A |
|
Petro Matad Ltd
LSE:MATD
|
-0.040x |
|
XM REALITY AB
F:5LL
|
N/A |
|
ALCHIMIE EO 1-
F:922
|
N/A |
|
Groupimo SA
PA:ALIMO
|
0.026x |
|
Abingdon Health Plc
LSE:ABDX
|
-0.181x |
Annual Cash Flow Conversion Efficiency for Vaxil Bio Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of Vaxil Bio Ltd from 2009 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$716.00K | CA$-240.00K | -0.335x | +46.76% |
| 2023-12-31 | CA$891.00K | CA$-561.00K | -0.630x | +2.55% |
| 2022-12-31 | CA$1.14 Million | CA$-734.00K | -0.646x | -1.33% |
| 2021-12-31 | CA$1.70 Million | CA$-1.08 Million | -0.638x | +53.52% |
| 2020-12-31 | CA$804.00K | CA$-1.10 Million | -1.372x | -234.20% |
| 2019-12-31 | CA$-583.00K | CA$-596.00K | 1.022x | +147.16% |
| 2018-12-31 | CA$435.00K | CA$-943.00K | -2.168x | -205.47% |
| 2017-12-31 | CA$-487.00K | CA$-1.00 Million | 2.055x | +190.01% |
| 2016-12-31 | CA$656.00K | CA$-1.50 Million | -2.284x | -179.41% |
| 2015-12-31 | CA$-217.00K | CA$-624.00K | 2.876x | +176.91% |
| 2014-12-31 | CA$34.48K | CA$-128.91K | -3.739x | -83.25% |
| 2013-12-31 | CA$187.94K | CA$-383.44K | -2.040x | +10.43% |
| 2012-12-31 | CA$72.15K | CA$-164.34K | -2.278x | -31.42% |
| 2011-12-31 | CA$264.09K | CA$-457.76K | -1.733x | -211.04% |
| 2010-12-31 | CA$682.06K | CA$-380.10K | -0.557x | -98.24% |
| 2009-12-31 | CA$515.90K | CA$-145.03K | -0.281x | -- |
About Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.